In the five-year multicentre, double-blind, randomised control trial, ATAC demonstrated that anastrozole was superior to tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer, with improved disease-free survival and a lower incidence of contralateral breast cancer [95]. This evidence concerns the gene NR4A1 and breast carcinoma.